Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity

Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not tumor cells. In this study, we sought t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Asnani, Aarti, Zheng, Bahoui, Liu, Yan, Wang, You, Chen, Howard H., Vohra, Anita, Chi, An, Cornella-Taracido, Ivan, Wang, Huijun, Johns, Douglas G., Sosnovik, David E., Peterson, Randall T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821184/
https://ncbi.nlm.nih.gov/pubmed/29321375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96753
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados